Lakewood-Amedex Biotherapeutics, Inc.
LABT
Lakewood-Amedex Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antimicrobial therapies for infectious diseases. Its current pipeline centers on the Bisphosphocin class, a novel group of broad-spectrum antimicrobials designed to address infections affecting the skin, bladder, lungs, and other serious bacterial conditions. The company’s lead program, Nu-3, is a topical antimicrobial being developed for infected diabetic foot ulcers, reflecting its emphasis on localized treatment options for hard-to-treat infections. Lakewood-Amedex Biotherapeutics also works on broader anti-infective applications aimed at antibiotic-resistant pathogens, positioning the company within the specialized biotechnology segment of the healthcare market. Headquartered in University Park, Florida, the company operates as a focused developer of next-generation antimicrobial products for unmet medical needs.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$7M
▲ +20.8% YoY
Op. Margin
–
ROIC
-254.41%
▲ +211.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$3M
▲ +66.0% YoY
Op. Cash Flow (TTM)
-$3M
▲ +60.4% YoY
Net Debt
$1M
Cash & Equiv.
$236K
Continue Research
Peers
Biotechnology · Pick stocks to compare with LABT
Lakewood-Amedex Biotherapeutics (LABT) in three numbers
Questions about Lakewood-Amedex Biotherapeutics
Is Lakewood-Amedex Biotherapeutics a high-quality business?
Lakewood-Amedex Biotherapeutics scores 0 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from company filings. Its best check is net debt at $1M. The Quality tab shows every check against its target.
Does Lakewood-Amedex Biotherapeutics (LABT) pay a dividend?
No. Lakewood-Amedex Biotherapeutics (LABT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing LABT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.